Mighty Therapeutics
PrivateLast Round
Take Private
Nov 16, 2022
Est. Valuation
$27.58M
Total Funding Raised
$160M
Company Overview
Mighty Therapeutics is a biotechnology company that develops and commercializes novel therapies for rare and age-related diseases involving mitochondrial dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Patient Engagement
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mighty Therapeutics Comparables
Compare Mighty Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astellas Pharma Inc. | 78% | |
| Khondrion | 77% | |
| Pretzel Therapeutics | 73% |
Mighty Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Take Private | Nov 16, 2022 | ||||
| Take Private | Aug 1, 2022 | ||||
| Private Placement | Apr 13, 2022 | ||||
| Private Placement | Apr 11, 2022 | ||||
| Debt | Oct 4, 2021 | ||||
Private Placement | Feb 10, 2021 |
Mighty Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| H.C. Wainwright & Co. | IPO |
| Morningside Ventures | Convertible Debt, Corporate Funding |
| Evercore | IPO |
| Atlantis Investment Management | Convertible Debt |
| CMBC Capital Holdings Limited | Convertible Debt |
| Sagamore Investments | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 16, 2022
Raised $10M with J. Wood Capital Advisors
- Apr 11, 2022
Raised $9M in a private placement round.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
Mighty is developing novel preclinical model for POLG mitochondrial disorders and Parkinson's disease on Sep 15th '26.
- partners_withSep 16, 2026
Mighty partnered with PolG Foundation on Sep 15th '26.
- partners_withSep 16, 2026
Mighty partnered with JAX on Sep 15th '26.
- is_developingSep 10, 2026
Mighty is developing MYTX-589 on Sep 10th '26.
- is_developingSep 10, 2026
Mighty is developing MYTX-255 for fatty acid oxidation disorders on Sep 9th '26.
Mighty Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Mighty Therapeutics's valuation, stock price, and market status.
Is Mighty Therapeutics a public or private company?
Mighty Therapeutics is a private company.
What is the current stock price of Mighty Therapeutics?
Mighty Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Mighty Therapeutics worth (valuation)?
Mighty Therapeutics's valuation is estimated at $27.6M based on funding round data.
Can I buy Mighty Therapeutics stock?
Mighty Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Mighty Therapeutics's last funding round?
Mighty Therapeutics's most recent funding round was Take Private on November 16, 2022.
Who are the main investors in Mighty Therapeutics?
Key investors in Mighty Therapeutics include Jefferies, Morningside Ventures, Evercore, Horizon Technology Finance Corporation, J. Wood Capital Advisors.
Will Mighty Therapeutics IPO soon?
No public IPO plans have been announced for Mighty Therapeutics.
How can I track Mighty Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mighty Therapeutics's secondary market activity and sign up for updates.